Minerva Neurosciences, Inc. Cash Flow Statement
NERV|8 years of annual SEC 10-K data (FY2017-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Minerva Neurosciences, Inc. used $20M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.64 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.4M | -$32.1M | -$49.9M | $1.9M | -$72.2M | -$50.2M | -$31.5M | -$27.1M |
| Depreciation & Amortization | $5.4K | $5.4K | - | $16.0K | $17.5K | $17.5K | $11.1K | $17.3K |
| Operating Cash Flow | -$19.6M | -$24.6M | -$24.6M | -$33.8M | -$43.4M | -$41.9M | $3.1M | -$24.3M |
| Capital Expenditures | - | $16.3K | $16.3K | - | - | - | $52.4K | $52.4K |
| Free Cash Flow | - | -$24.7M | -$24.6M | - | - | - | $3.0M | -$24.3M |
| Share Buybacks | - | - | - | - | - | - | $389 | $389 |